Validation of a ctDNA-Based comprehensive genomic profiling panel (IST80 Plus) for advanced non-small cell lung cancer.
Blood tests can now reliably detect cancer-related DNA patterns with high accuracy, offering a non-invasive way to monitor disease.
We evaluated the analytical and clinical performance of Illumina Solid Tumor Panel 80 (IST80 Plus), a focused hybrid-capture next-generation sequencing assay for plasma genomic profiling. IST80 Plus showed high sensitivity and quantitative accuracy for small variants and reliable fusion detection in ctDNA.
What the study was
- Study design
- Validation study
- Population
- Validation included Seraseq-ctDNA reference materials at 2.5% and 0.5% allele frequencies, six external quality-assessment samples, supernatants from three fusion-positive cell lines, and eighteen plasma samples from patients with previously characterized NSCLC alterations.
- Category
- Early Detection
- Maturity
- Validated
- Journal
- The journal of liquid biopsy
Why it surfaced
Validation study assessed from PubMed metadata and abstract text; conservatively scored 8/10 under the v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.